Business
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France. T
About this update from Autonomix Medical, Inc.
[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8proYv7.6K9ADbheu_vN6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NA--/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/8proYv7.6K9ADbheu_vN6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NA--/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France.","length":503,"tagName":"p"},{"type":"text","content":"The accepted abstracts titled, “Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation” and “Illuminating the nervous system with transvascular precision-guided technology”, further recognize the growing clinical and scientific interest in Autonomix’s differentiated approach to peripheral nerve modulation and pain mitigation.","length":367,"tagName":"p"},{"type":"text","content":"“These abstract acceptances at EuroPCR underscore the expanding interest in precision-guided, transvascular approaches to peripheral nerve targeting,” said Brad Hauser, Chief Executive Officer of Autonomix. “We believe participation at premier international scientific forums such as EuroPCR is important to advancing awareness of our platform technology and its potential applicability across multiple disease states where nerve signaling plays a critical role.”","length":463,"tagName":"p"},{"type":"text","content":"Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix, added, “The acceptance of two abstracts re...